Global / 3 Pfizer Country Managers on COVID-19 Vaccine Rollout & Learnings
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with…
Top Stories
Singapore / New Pharma Country Report Download 2021
With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a…
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
Europe / Top 5 Pharma R&D Spenders
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest…
CEE / EU5/CEE Healthcare Disparity; Novavax's Big Czech Investments; Polish Vaccine Hesitancy a Boon for Aussies
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the…
Denmark / 5 Pharma Country Managers Talk Market Access
Long established as a premier early launch country for innovative medicines within Europe, the Danish market access…
Canada / Concrete Steps Toward National Pharmacare
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific…
Latest Reports
In Conversation
Ahmed Alaskar – Executive Director, KAIMRC, Saudi Arabia
Dr Ahmed Alaskar is executive director of the King Abdullah International Medical Research Center (KAIMRC); president of the Saudi Society of Blood and Marrow Transplantation (SSBMT); professor of Consultant Adult Hematology & HSCT at King Saud bin Abdulaziz University for Health Sciences; and chairman of the Riyadh Global Medical Biotechnology Summit 2021. Here, Dr Alaskar presents what Saudi Arabia has…
Tore von Würden – Country Director Denmark &…
Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not…
Catherine Williams – Managing Director, MSD Denmark…
MSD’s Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market,…
Focus on USA
Note to Biogen: Your Marketing is Showing
In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’…
Inserting the Patient Voice: Ethical Challenges in the Use…
Patient advocate and regular PharmaBoardroom contributor Monica Weldon examines how healthcare’s data revolution has thus far largely ignored the patient voice and argues for a more inclusive approach to drive…
Impact of COVID-19 on US Clinical Studies Conducted by…
Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies. The…
US Health Policy: FDA Calls for Federal Investigation of…
The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed Advanced Research Projects Agency that would reshape…
Read more: USA >>
Focus on Vaccines
Spain Pharma News: Grifols Invests in Nigerian…
The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP protection for medical advancements, Grifols’ expansion in Africa through a manufacturing plant in…
Enough COVID Vaccines for World Population Says IFPMA: Calls…
Pharma industry leaders have called for rich nations to stop stockpiling excess COVID-19 vaccine doses and stated that there will be enough production by the end of the year to…
The COVID-19 Pandemic in Japan: Treatments, Vaccines &…
Writing in the August edition of DIA’s Global Forum, Kotone Matsuyama of the Nippon Medical School gives a run-through of Japan's response to the COVID-19 pandemic, from the organisation and communication…
3 Pfizer Country Managers on COVID-19 Vaccine Rollout &…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
Read more: Vaccines >>
Focus on APAC
APAC: Self-Medication in the Age of COVID: The…
Writing in the May edition of DIA’s Global Forum magazine, Toshiyoshi Tominaga of the Asia-Pacific Self-Medication Industry (APSMI) looks at the landscape for OTC medicines in the Asia-Pacific region today. Tominaga highlights…
Decentralised Clinical Trials in APAC Here to Stay
Writing in the July issue of DIA’s Global Forum magazine Serene Ong and Gaurang Majmudar of clinical trial logistics specialists Marken outline why the shift to decentralised clinical trials brought…
3 Pfizer Country Managers on COVID-19 Vaccine Rollout &…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
Regulatory Cooperation & Joint Assessments in ASEAN
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia's National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
Read more: APAC >>
Focus on Saudi Arabia
Pharma Faces: Dimitri Livadas, Lilly Saudi Arabia
Having commenced his journey with American giant Lilly in 2008, and after almost eight years working in the company’s Japan organization, mostly on digital marketing, Dimitri Livadas crossed the Pacific…
Top 2021 Insights from Global Regulators
Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top…
Three Key Trends to Watch in Saudi Arabia’s Pharma…
Looking to diversify its economy while simultaneously improving its healthcare system, Saudi Arabia has been rolling out incentives for international companies to invest in local manufacturing. Here are three trends…
3 Pfizer Country Managers on COVID-19 Vaccine Rollout &…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
Read more: Saudi Arabia >>
Focus on Europe
Sweden as a Global Testbed for AMR Incentive Models
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
Top 5 Pharma R&D Spenders in Europe
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
Europe Pharma Industry Top 5 Rankings 2021
Drawing from the 2021 edition of the EFPIA's comprehensive annual data review of the European pharma industry, we present the Top 5 countries across a variety of pharma metrics: from…
Top 2021 Insights from Global Regulators
Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top…
Read more: Europe >>
Focus on China
PharmaBoardroom’s Top 5 Op-Eds in 2021 (So Far)
As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These…
China News Roundup: Sinopharm Looks to mRNA Vaccines; Hong…
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…
PhIRDA’s Song Ruilin on Strengthening China’s Drug…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks out the key learnings from recent legislation to improve China’s drug regulatory capacity and why it…
China Pharma News: Fosun Sales up 20%; MNC Price Manoeuvres…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in…
Read more: China >>
Focus on Turkey
Top 2021 Insights from Global Regulators
Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top…
Pharma Faces: Demet Russ, Janssen Turkey
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Turkey’s Moment of Reckoning on Diabetes?
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
Turkey: A Pharma Talent Hotbed
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…